Wellington Management Company, an investment management company, led a $116M Series V funding round in Entrada Therapeutics, a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics. Additional investors include Redmile Group, TCG Crossover, Greenspring Associates, Point72, Qatar Investment Authority, Moore Strategic Ventures, Goldman Sachs, CureDuchenne Ventures, 5AM Ventures, MPM Capital, Roche Venture Fund, MRL Ventures Fund and Agent Capital. “We are pleased to have such strong support from outstanding investors. Their commitment is a testament to the potential of the Company’s platform and pipeline. This investment will allow us to advance our research and a growing pipeline of intracellular oligonucleotide, antibody and enzyme-based therapeutics which we hope will transform the lives of patients living with devastating diseases," Dipal Doshi, Entrada Therapeutics President and Chief Executive Officer.